GSK says FDA declines to approve higher dose Advair
NEW YORK, Aug 8 (Reuters) - GlaxoSmithKline Plc. (GSK.L: Quote, Profile, Research, Stock Buzz) said on Wednesday that U.S. health regulators declined to approve a higher strength version of its inhaled Advair Diskus for the treatment of chronic obstructive pulmonary disease (COPD).
Europe's largest drugmaker said it received a non-approvable letter from the Food and Drug Administration for the 500/50 strength version of the medicine even after an advisory panel had unanimously recommended approval. The 250/50 Advair Diskus was approved in 2003 for maintenance treatment of airflow obstruction in COPD patients.
The FDA questioned how Advair 500/50 compared to the currently approved 250/50 strength in order to allow for appropriate dosing recommendations, Glaxo said. (Reporting by Bill Berkrot)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.




